Stockreport

Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics, Inc.  (OTLK) 
Last outlook therapeutics, inc. earnings: 2/14 08:00 am Check Earnings Report
PDF LYTENAVA™ (bevacizumab gamma) becomes first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet AMDEuro [Read more]